Pfizer Inc

NYSE: PFE
$25.83
+$0.06 (+0.2%)
Closing Price on November 27, 2024

PFE Articles

Pharmaceutical giants Merck and Pfizer are expected to report their most recent quarterly results before the opening bell Tuesday.
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Exxon, Microsoft and Pfizer above all other Dow stocks.
Over one-third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. Here's what to expect.
BioNTech shares shot up on Wednesday after the company announced, in conjunction with Pfizer, that its COVID-19 vaccine program was approved in Germany.
The March 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Exxon, Microsoft and Pfizer above all other Dow stocks. It was a period in which short interest in these stocks was shrinking handily,...
Pfizer and BioNTech each saw gains on Thursday after the companies announced additional details regarding their collaboration in the fight against COVID-19.
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Friday's top analyst upgrades and downgrades included American Airlines, Chipotle Mexican Grill, Ericsson, Microsoft, Mylan, Novavax, Pfizer, Procter & Gamble, Qualcomm, Square and Starbucks.
BioNTech stock jumped on Tuesday and went even higher early on Wednesday. This comes after the company announced a collaboration with the pharmaceutical giant Pfizer.
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Pfizer, Intel and Exxon above all other Dow stocks.
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Cree, Etsy, Gilead Sciences, Pfizer, Rite Aid, Solar Edge, Square, 3D Systems and Virgin Galactic.
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.